Загрузка...

EGFR mutation heterogeneity and mixed response to EGFR tyrosine kinase inhibitors of non small cell lung cancer: a clue to overcoming resistance

The presence of an EGFR activating mutation is predictive of benefit from reversible and irreversible EGFR tyrosine kinase inhibitor (EGFR-TKI) allowing personalized medicine in lung cancer. However, intratumoral heterogeneity in EGFR mutation status has recently been described and ranged from 13.9%...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Transl Lung Cancer Res
Главные авторы: Remon, Jordi, Majem, Margarita
Формат: Artigo
Язык:Inglês
Опубликовано: Pioneer Bioscience Publishing Company 2013
Предметы:
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4367629/
https://ncbi.nlm.nih.gov/pubmed/25806267
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2013.10.14
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!